Effect of a SGLT2 inhibitor on the systemic and intrarenal renin–angiotensin system in subtotally nephrectomized rats

Journal of Pharmacological Sciences

Volumn 137, Issue 2, 2018, Pages 220-223

  Li, Lei ^a   Konishi, Yoshio ^b   Morikawa, Takashi ^b   Zhang, Yifan ^a   Kitabayashi, Chizuko ^b   Kobara, Hideki ^a   Masaki, Tsutomu ^a   Nakano, Daisuke ^a   Hitomi, Hirofumi ^a   Kobori, Hiroyuki ^c   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Chronic kidney disease (CKD); Renin angiotensin system (RAS); SGLT2 inhibitor

Indexed keywords

ANGIOTENSIN II; ANGIOTENSINOGEN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TA 1887; UNCLASSIFIED DRUG; GLUCOSIDE; INDOLE DERIVATIVE; RENIN; SGLT2 PROTEIN, RAT; SODIUM GLUCOSE COTRANSPORTER 2;

ANGIOTENSINOGEN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HORMONE ACTION; HORMONE BLOOD LEVEL; KIDNEY INJURY; KIDNEY TISSUE; MALE; NEPHRECTOMY; NONHUMAN; PLASMA RENIN ACTIVITY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; KIDNEY; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANGIOTENSINOGEN; ANIMALS; DISEASE MODELS, ANIMAL; GLUCOSIDES; GLYCOSURIA; INDOLES; KIDNEY; MALE; NEPHRECTOMY; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85046165406     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2017.10.006     Document Type: Article

References (15)

1. Vallon, V., Platt, K.A., Cunard, R., et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:1 (2011), 104–112.
2. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:22 (2015), 2117–2128.
3. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:4 (2016), 323–334.
4. Haneda, M., Seino, Y., Inagaki, N., et al. Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus. Clin Ther 38:1 (2016), 66–88 e20.
5. Rahman, A., Kittikulsuth, W., Fujisawa, Y., et al. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. J Hypertens 34:5 (2016), 893–906.
6. Takeshige, Y., Fujisawa, Y., Rahman, A., et al. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Hypertens Res 39:6 (2016), 415–422.
7. Yale, J.F., Bakris, G., Cariou, B., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:5 (2013), 463–473.
8. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86:5 (2014), 1057–1058.
9. Mizushige, T., Kobori, H., Hitomi, H., et al. Urinary angiotensinogen could Be a prognostic marker of the renoprotection of olmesartan in metabolic syndrome patients. Int J Mol Sci, 17(11), 2016.
10. Kobori, H., Nangaku, M., Navar, L.G., Nishiyama, A., The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59:3 (2007), 251–287.
11. Shin, S.J., Chung, S., Kim, S.J., et al. Effect of sodium-glucose Co-Transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One, 11(11), 2016, e0165703.
12. Zhang, Y., Thai, K., Kepecs, D.M., Gilbert, R.E., Sodium-glucose linked Cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS One, 11(1), 2016, e0144640.
13. Oguma, T., Kuriyama, C., Nakayama, K., et al. Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents. J Pharmacol Sci 132:4 (2016), 255–261.
14. Ohnishi, K., Murase, M., Nakano, D., et al. Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats. J Pharmacol Sci 122:2 (2013), 103–108.
15. Gallo, L.A., Ward, M.S., Fotheringham, A.K., et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep, 6, 2016, 26428.